[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to predict watchful waiting duration in patients with metastatic clear cell renal cell carcinoma.
Sarah R VerhoeffSjoukje F OostingSjoerd G EliasElisabeth G E de VriesSophie L GerritseLindsay AngusSandra HeskampIngrid M E DesarCatharina Willemien Menke-van der Houven van OordtAstrid A M van der VeldtAnne I J ArensAdrienne H BrouwersBertha EissesPeter F A MuldersOtto S HoekstraGerben J C ZwezerijnenWinette T A van der GraafErik H J G AarntzenWim J G OyenCarla M L van HerpenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
In patients with good or intermediate risk mccRCC, low [18F]FDG-uptake is associated with prolonged WW. This study shows the predictive value of the "W&W-criteria" for WW duration and shows the potential of [18F]FDG-PET/CT to further improve this.